
- Industry news
Industry news
Trending now
- Category news
- Reports
Trending now
- Key trends
Trending now
- Multimedia
Multimedia
Trending now
- Journal
- Events
Trending now
- Suppliers
Suppliers
Trending now
- Home
- Industry news
Industry news
Trending now
- Category news
- Reports
Trending now
- Key trends
Trending now
- Multimedia
Multimedia
Trending now
- Events
Trending now
- Suppliers
Suppliers
Trending now
Meta-Analysis Confirms Effectiveness of BioGaia’s Probiotic For Infant Colic

13 Jan 2016 --- In a newly published systematic review the proof of effect on infant colic was further strengthened for L. reuteri Protectis. The review evaluated 17 studies of different treatments of infant colic, whereof L. reuteri Protectis was the only probiotic. Only one other product was deemed effective. Simethicone, a drug often prescribed for colic, was shown to have no effect.
Prior to the new review four meta-analyses, evaluating different probiotics as well as non-probiotic treatments, have come to the same conclusion; that L. reuteri Protectis is effective in colic, especially in breastfed and mixed fed infants. In the new, fifth review, with 6 studies on L. reuteri Protectis included, the proof was further strengthened.
”The new meta-analysis once again confirms our position as the number one treatment for infants with colic. Today health care professionals around the world can be totally reassured that they are suggesting an effective treatment when recommending BioGaia ProTectis drops to their patients”, says Peter Rothschild, President, BioGaia.







